OSE Immunotherapeutics announced that the company is committed to the fight against COVID-19. Its team of immunologists is actively working on the development of a prophylactic vaccine against the pandemic virus SARS-CoV-2.
OSE Immunotherapeutics leverages its expertise in the selection and optimization of peptides of interest and their GMP formulation for a specific type of combination of multiple peptides. The company uses the know-how from its Memopi® epitope (neo-epitope) optimization technology, recently successfully validated in the first step of a Phase 3 clinical testing for Tedopi®, a combination of antitumor neo-epitopes, to increase the memory immune response of T lymphocytes against specific antigens.
Using bioinformatics approaches and algorithms for predicting immunogenicity in the virus genome, OSE Immunotherapeutics’ R&D team has screened a large number of peptides derived from different proteins of SARS-CoV-2, SARS-CoV and MERS-CoV and selected the immuno-dominant epitopes from 4 major proteins of coronaviruses...
Full text at GMPnews.Net